Stock UniverseDerived research view · source repositories remain read-only

UroGen Pharma Ltd. (URGN)

Therapeutics / Biopharma · Healthcare / Biotechnology
Score Band
Qualified
Selection Score
36.77
Global Rank
944
Market Cap
1.02B
Latest Close
26.85
RS Composite
18.72% · G#484

Price Movement

3Y daily adjusted close
Loading price data...
Adjusted close SMA60D
1M
2.29%
3M
31.23%
6M
10.27%
1Y
445.73%
3Y
171.21%
5Y
52.38%
10Y
92.06%

Volume

Loading volume data...
Volume Volume MA20D

Latest volume: 663.87K · 30-day average: 814.98K · Max drawdown over stored range: -93.98%

Research Snapshot

Relative Strength vs SPX

RS Composite18.72%
20D RS0.34%
60D RS33.54%
120D RS13.09%
Global RS Rank484 · 85.57% percentile
Qualified+ RS Rank197 · 84.34% percentile
Group ScopeQualified+
Primary RS Rank72 · 84.28% percentile
Snapshot Date2026-06-05

RS uses adjusted close where available. Global RS Rank is recalculated from the current non-low pool. Group RS Rank is recalculated inside the company’s own actionable band group.

Research Links

StockAnalysis
Yahoo Finance
Perplexity Finance
Finviz
Seeking Alpha
WhaleWisdom
FinanceCharts
SEC EDGAR Search
SEC Company Search

Official company website and investor-relations URLs are not inferred unless a reliable dynamic source is added.

Classification

Primary Rank173 / 701
Primary Percentile75.46
Score Notesmarket-cap support, industry-tailwind

Gemini Deep Research

Loading Gemini reports...

Manual Estimates

Loading manual estimates...

Forward Valuation

Loading forward valuation...

SEC TTM Fundamentals

PeriodFiledRevenueGross ProfitOperating IncomeNet IncomeEPS DilutedOperating Cash FlowCapital ExpenditureFree Cash FlowShares DilutedGross MarginOperating MarginNet MarginOCF MarginFCF MarginCash + ST Inv.Total Debt
TTM through 2026-03-312026-05-06140.49M126.24M-108.21M-133.22Mn/a-289.61M528.00K-290.14M0M89.85%-77.02%-94.83%-2.06%-2.07%149.71M189.53M

SEC TTM. Read-only SEC TTM snapshot. Shares Diluted is the rolling average across the four-quarter window.

TTM Valuation

PeriodEPS DilutedP/ERevenue / ShareP/SFCF / ShareP/FCF MultipleOCF / ShareP/CF Multiple
TTM through 2026-03-31n/an/an/an/an/an/an/an/a

Shares Diluted: 0M. SEC TTM. Read-only SEC TTM snapshot. Shares Diluted is the rolling average across the four-quarter window.

Financial Statement Metrics

MetricFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue11.79948.04264.35782.71390.398109.788
Revenue Growth (YoY)65450.0%307.17%33.96%28.522%9.291%21.45%
Gross Profit10.7942.88556.70373.35281.517
Operating Income-120.139-92.292-79.041-65.536-95.682
Free Cash Flow-107.101-85.644-87.813-76.57-97.061-162.733
Free Cash Flow Per Share-4.917-3.832-3.85-2.656-2.264-3.3820905427534877
EPS (Diluted) GAAP-5.898949-4.958948-4.813605-3.545915-2.95904
EPS Growth
EPS Non-GAAP
Gross Margin91.448%89.266%88.107%88.683%90.176%88.6627%
Operating Margin-1018.213%-192.107%-122.816%-79.233%-105.845%-113.731%
Profit Margin-1088.94%-230.673%-170.584%-123.613%-140.35%-139.8095%
Free Cash Flow Margin-907.713%-178.269%-136.447%-92.573%-107.371%-148.2248%
Shares Outstanding (Diluted)21.780822.347522.806828.834342.876748.1161
Shares Change (YoY)6.099%2.602%2.055%26.428%48.7%12.22%

SEC Quarterly Fundamentals

Revenue + Operating Margin
Loading SEC quarterly chart...
Revenue Operating Margin
Quarter Filed Revenue Gross Margin Operating Income Op Margin Net Income Net Margin EPS Diluted Shares Diluted Cash + ST Inv. Total Debt Confidence
2026 Q12026-05-0650.96M91.88%-20.26M-39.76%-23.57M-46.26%n/an/a149.71M189.53Mprocessed
2025 Q42026-03-0237.84M91.31%-19.11M-50.52%-26.36M-69.68%n/an/a160.06M122.21Mprocessed
2025 Q32025-11-0627.48M88.07%-27.39M-99.65%-33.35M-1.21%n/an/a153.83M122.11Mprocessed
2025 Q22025-08-0724.21M85.34%-41.45M-1.71%-49.94M-2.06%n/an/a176.01M122.51Mprocessed
2025 Q12025-05-1220.25M88.50%-36.91M-1.82%-43.84M-2.16%n/an/a216.06M122.11Mprocessed
2024 Q42025-03-1024.57M89.94%-27.66M-1.13%-37.51M-1.53%n/an/a282.66M121.73Mprocessed
2024 Q32024-11-0625.20M90.27%-17.55M-69.61%-23.67M-93.93%n/an/a278.85M121.71Mprocessed
2024 Q22024-08-1321.85M89.80%-25.84M-1.18%-33.40M-1.53%n/an/a272.25M97.81Mprocessed
2024 Q12024-05-1318.78M90.80%-25.74M-1.37%-32.29M-1.72%n/an/a183.16M97.59Mprocessed
2023 Q42024-03-1423.53M90.28%-14.61M-62.09%-26.02M-1.11%n/an/a151.16M98.55Mprocessed
2023 Q32023-11-1420.85M88.65%-13.50M-64.74%-21.88M-1.05%n/an/a174.60M98.52Mprocessed
2023 Q22023-08-1021.14M88.44%-15.38M-72.77%-24.14M-1.14%n/an/a56.02M98.30Mprocessed
2023 Q12023-05-1117.19M86.83%-22.05M-1.28%-30.21M-1.76%n/an/a75.92M97.94Mprocessed
2022 Q42023-03-2418.09M87.49%-20.28M-1.12%-28.87M-1.60%n/an/a55.41M97.54Mprocessed
2022 Q32022-11-1016.10M87.45%-18.09M-1.12%-25.83M-1.60%n/an/a28.69M71.87Mprocessed
2022 Q22022-08-1116.60M88.88%-18.71M-1.13%-26.69M-1.61%n/an/a80.69M71.20Mprocessed
2022 Q12022-05-1013.56M88.76%-21.96M-1.62%-28.39M-2.09%n/an/a105.38M70.80Mprocessed
2021 Q42022-03-2116.17M90.18%-19.91M-1.23%-28.45M-1.76%n/an/a44.36Mn/aprocessed
2021 Q32021-11-1511.35M89.04%-23.44M-2.07%-30.21M-2.66%n/an/a55.34Mn/aprocessed
2021 Q22021-08-0413.03M89.05%-22.82M-1.75%-26.22M-2.01%n/an/a63.32Mn/aprocessed

SEC processed quarterly CSV. Compact derived quarterly view from SEC processed CSV. Source files remain read-only in the SEC repository. EPS is as filed and may not be split-adjusted across older periods. StockAnalysis Financial Statement Metrics remain unchanged above.